JAMA Oncology

JAMA Oncology is a member of the JAMA Network, a consortium of peer-reviewed, general medical and specialty publications.

[JAMA Oncology @JAMAOnc]

A phase 3 trial shows serplulimab plus chemotherapy improved overall survival and 4-year survival rates vs chemotherapy alone in extensive-stage small cell #LungCancer, with durable benefit and manageable safety. https://t.co/iGTsqYyovq

[JAMA Oncology @JAMAOnc]

Oral upadacitinib achieved rapid resolution and pruritus relief in severe immune checkpoint inhibitor–related #Dermatitis, with no serious treatment-related adverse events.

https://t.co/52i1Sbr1sw

[JAMA Oncology @JAMAOnc]

A meta-analysis found first-line chemoimmunotherapy provided longer overall and progression-free survival than PD-(L)1 inhibitor monotherapy in advanced #NSCLC with high #PDL1, though with greater toxicity. https://t.co/0doQhIrwi5

[JAMA Oncology @JAMAOnc]

A meta-analysis found first-line chemoimmunotherapy provided longer overall and progression-free survival than PD-(L)1 inhibitor monotherapy in advanced #NSCLC with high #PDL1, though with greater toxicity. https://t.co/JehoSISuhO

[JAMA Oncology @JAMAOnc]

This JAMA Oncology Patient Page discusses benefits and risks of local consolidative therapy for metastatic #LungCancer and which patients might be considered for this treatment. https://t.co/8DAUoBMfLh

[JAMA Oncology @JAMAOnc]

Oral upadacitinib achieved rapid resolution and pruritus relief in severe immune checkpoint inhibitor–related #Dermatitis, with no serious treatment-related adverse events. https://t.co/vb1u8yOOhz

[JAMA Oncology @JAMAOnc]

From @JAMA_current: In resected non-small cell lung #cancer, adjuvant #nivolumab following standard care was not associated with improved survival or recurrence risk compared with observation, even in #tumors with high PD-L1 expression.

#ASCO26 @ASCO

https://t.co/3f8lLL1jJv

[JAMA Oncology @JAMAOnc]

🌟Fovinaciclib for First‑Line Therapy for Advanced Breast Cancer: A Randomized Clinical Trial, presented today at #ASCO26

📖 Free to read online from @JAMAOnc

https://t.co/Ro5fwncY50

[JAMA Oncology @JAMAOnc]

A phase 3 trial demonstrated that fovinaciclib plus aromatase inhibitor showed significant and clinically improved progression-free survival with manageable safety in hormone receptor–positive, ERBB2-negative advanced #BreastCancer.

#ASCO26 @ASCO

https://t.co/2XT5EUvh4g

[JAMA Oncology @JAMAOnc]

A 69-year-old male patient presented with worsening new-onset oral ulcerations and pain. He had myelodysplastic syndrome and underwent an allogeneic hematopoietic stem cell transplant 18 months prior. What is your diagnosis? See the answer: https://t.co/54wuzkRnm1

[JAMA Oncology @JAMAOnc]

✨Impact of Population‑Based Pathogenic Variant Testing on Risk‑Based Breast Screening Recommendations: A Secondary Analysis of the WISDOM Study, presented today at #ASCO26

📖 Free to read online from @JAMAOnc

https://t.co/NKegGBSo3R

[JAMA Oncology @JAMAOnc]

Among women with breast cancer gene pathogenic variants (PV), most would not have received high-risk screening based on clinical or polygenic risk, supporting the need for germline PV testing in risk-based #BreastCancer screening.

#ASCO26 @ASCO

https://t.co/LE9jrMP5Z0

[JAMA Oncology @JAMAOnc]

Older adults with advanced cancer mainly prioritized quality of life, but their treatment preferences were not associated with differences in survival, hospitalization, or adverse effects. https://t.co/n1c9pvbkpV

[JAMA Oncology @JAMAOnc]

Study of veterans with cancer identified high rates of suicidal self-directed violence, with greatest risk in younger, female, American Indian or Alaska Native, and those with central nervous system, pancreas, liver, thyroid, or head and neck cancer.

https://t.co/1CHwZQ2vyi

[JAMA Oncology @JAMAOnc]

This Review examines the clinical utility of circulating tumor DNA assays for detecting minimal residual disease in patients with early-stage breast cancer.

https://t.co/aNP1IUY4sR

[JAMA Oncology @JAMAOnc]

Sequential radiotherapy and immunotherapy (#iRT) provided longer overall survival than concurrent iRT for newly diagnosed advanced non–small cell lung cancer, with additional benefit from chemotherapy.

https://t.co/dWT4cR4GT9

[JAMA Oncology @JAMAOnc]

✨Attending #ASCO26?
🌟 Explore our attendee page for the latest articles
🎧 Listen to podcasts
📚 Get For Authors resources from @JAMA_current, @JAMAOnc, and @JAMANetworkOpen

https://t.co/y1XoTqlFcw

[JAMA Oncology @JAMAOnc]

PRIME is a validated, interpretable #PancreaticCancer risk model using routine clinical data, supporting risk-based case-finding and integration with biomarker testing for early detection. https://t.co/rqtjCmb3wE

[JAMA Oncology @JAMAOnc]

In 2025, JAMA Oncology received 3738 manuscripts from 74 countries, with original scientific content impacting patient care, research, and policy.

Read the full Year in Review by JAMA Oncology Editor in Chief Mary L. (Nora) Disis, MD. https://t.co/NVjlLddVrZ

[JAMA Oncology @JAMAOnc]

Bireociclib plus fulvestrant improved progression-free survival and objective response in hormone receptor–positive, ERBB2-negative advanced #BreastCancer after endocrine progression. https://t.co/pQs6FeBqNm